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Abstract
Background: The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand
differences among these JAK inhibitors (JAKis) at the cellular level.
Methods: Peripheral blood mononuclear cells from healthy donors were incubated with different JAKis, levels of
phosphorylated signal transducer and activator of transcription (pSTAT) were measured following cytokine
stimulation, and half maximum inhibitory concentration (IC50) values were calculated in phenotypically gated
leukocyte subpopulations. Therapeutic dose relevance of the in vitro analysis was assessed using calculated mean
concentration-time profiles over 24 h obtained from JAKi-treated subjects. Time above IC50 and average daily
percent inhibition of pSTAT formation were calculated for each JAKi, cytokine, and cell type.
Results: Distinct JAKis displayed different in vitro pharmacologic profiles. For example, tofacitinib and upadacitinib
were the most potent inhibitors of the JAK1/3-dependent cytokines tested (interleukin [IL]-2, IL-4, IL-15, and IL-21)
with lower IC50 values and increased time above IC50 translating to a greater overall inhibition of STAT signaling
during the dosing interval. All JAKis tested inhibited JAK1/2-dependent cytokines (e.g., IL-6 and interferon [IFN]-γ),
the JAK1/tyrosine kinase 2 (TYK2)-dependent cytokines IL-10 and IFN-α, the JAK2/2-dependent cytokines IL-3 and
granulocyte-macrophage colony-stimulating factor (GM-CSF), and the JAK2/TYK2-dependent cytokine granulocyte
colony-stimulating factor (G-CSF), but often to significantly differing degrees.
Conclusions: Different JAKis modulated distinct cytokine pathways to varying degrees, and no agent potently or
continuously inhibited an individual cytokine signaling pathway throughout the dosing interval. Notably, baricitinib
inhibited JAK1/3 signaling to a lesser extent than upadacitinib and tofacitinib, while upadacitinib, baricitinib, and
tofacitinib inhibited the signaling of JAK2/2-dependent cytokines, including GM-CSF and IL-3, as well as the
signaling of the JAK2/TYK2-dependent cytokine G-CSF.
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Background
The Janus kinase (JAK) family of cytoplasmic protein
tyrosine kinases comprises JAK1, JAK2, JAK3, and tyro-
sine kinase 2 (TYK2). Janus kinases bind to type l and
type ll cytokine receptors and transmit extracellular
cytokine signals to activate signal transducers and activa-
tors of transcription (STATs), which translocate to the
nucleus and modulate transcription of effector genes [1].
Recent advances in the treatment of rheumatoid arthritis
(RA) have been made with the use of small molecules
that inhibit JAKs, specifically targeting cytokine signaling
pathways implicated in RA pathogenesis [2–5].
Baricitinib and tofacitinib are JAK inhibitors (JAKis)
that have been approved for the treatment of RA, and
other JAKis, including upadacitinib, are in clinical devel-
opment [2]. Baricitinib is approved for the treatment of
moderately to severely active RA in adults in over 60
countries including European countries, Japan, and the
USA. In vitro kinase assays demonstrate that baricitinib
is a selective JAK1 and JAK2 inhibitor with moderate ac-
tivity against TYK2 and significantly less against JAK3
[6]. Tofacitinib is a potent JAK1 and JAK3 inhibitor but
is less active against JAK2 and TYK2 [7]. Upadacitinib is
reported as a selective JAK1 inhibitor [8, 9]. Distinct
cytokine signaling pathways are mediated by varying
JAK complexes, indicating that various JAKis may have
differing effects on host inflammatory responses, includ-
ing those that drive RA.
Herein, we sought to study JAKis that have shown clin-
ical efficacy in the treatment of RA and other autoimmune
diseases. The objective of the study was to compare the in
vitro cellular pharmacology of baricitinib, upadacitinib,
and tofacitinib across relevant leukocyte subpopulations,
coupled with their in vivo pharmacokinetics (PK), to de-
termine their effects on distinct cytokine pathways, many
implicated in RA pathogenesis.
Methods
Leukocyte preparation and experimental design
Whole blood samples from healthy donors (N = 4–12) were
apheresed, and leukocyte-enriched fractions containing ap-
proximately 400 million leukocytes were transferred to the
company Primity Bio (Fremont, CA, USA). Immediately
following apheresis, approximately 600,000 cells were
plated in 100 μL into 96-well plates and incubated with
JAKis using a 7-point dose range from 2 to 10,000 nM
(four-fold dilutions from the highest concentration) for 1 h
prior to stimulation with cytokines for 15min at 37 °C.
Laboratory procedures ensured that compound incubation
and cytokine stimulation times were kept constant across
cytokines and donors, including when multiple donor
samples were being processed. Baricitinib (Eli Lilly and
Company), upadacitinib (synthesized by Eli Lilly), and tofa-
citinib citrate (ApexBio) were prepared as 10-mM stocks in
dimethyl sulfoxide. Eight cytokines were used at a concen-
tration of 30 ng/mL (granulocyte colony-stimulating factor
[G-CSF], interferon [IFN]-γ, interleukin [IL]-2, IL-4, IL-6,
IL-10, IL-15, and IL-21); three others were used at different
concentrations: granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) (15 pg/mL), IFN-α (5 ng/mL),
and IL-3 (2 ng/mL). For the first eight cytokines, data
were generated in two batches; one batch compared
baricitinib to tofacitinib (6 donors) and a second batch
compared baricitinib to upadacitinib (6 donors). For
the remaining cytokines, data were generated in three
batches; one batch compared baricitinib to upadacitinib
(6 donors) and two other batches compared baricitinib
to tofacitinib (2 donors/batch). The choice of cytokine
concentrations and incubation conditions were opti-
mized in order to ensure consistent signaling in alter-
nate cell types and phosphorylated STAT (pSTAT)
readouts.
Flow cytometry
After stimulation, cells were fixed, permeabilized, and fluor-
escence barcoded as previously described [10]. Samples
were combined and stained with fluorochrome-conjugated
pSTAT1 (Y701), pSTAT3 (Y705), pSTAT5 (Y694), pSTAT6
(Y641), CD3, CD4, CD20, and CD56 antibodies. Multicolor
flow cytometry was used to quantify STAT phosphorylation
in gated leukocyte subpopulations, and the signals from
each sample were de-barcoded for statistical analysis. For a
given case (stimulation, cell type, and pSTAT combination),
the half maximum inhibitory concentration (IC50) was de-
termined if there was a consistent response to the stimulus
as described in the “Statistical analysis” section. The pri-
mary pSTAT observed for each stimulus is reported.
Leukocyte populations were defined as CD20+ (B cells),
CD3+CD4+ (CD4+ T cells), CD3+CD4− (CD8+ T cells),
CD3−CD56+ (natural killer [NK] cells), and by forward and
side scatter (monocytes).
Statistical analysis
The IC50 values for JAKis were determined by analyzing
the mean fluorescence intensity (MFI) of cytokine-stim-
ulated samples in the presence of the designated concen-
tration of compound. For a given case (stimulation, cell
type, and pSTAT combination), the MFI for unstimu-
lated and stimulated cells was determined for each
donor. To ensure that a biologically relevant signal was
induced, concentration-response curves (CRCs) were
only analyzed when a consistent response to stimulus
was observed as described below. Data were analyzed
with a statistical model using an integrated data set that
included a model term to account for any systematic
batch effects.
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Selection of cases for analysis, fitting, and selection of CRC
curves
Two sets of criteria for reporting an IC50 value were used:
one at the case level and another at the individual curve
level. For the CRCs to be estimated for a given case, the
case had to satisfy two criteria: (c1) the minimum MFI
difference between stimulated and unstimulated reads
across all donors was at least 10 fluorescence units and
(c2) the p value of the one-sided t test of the null hypoth-
esis stimulated < unstimulated was at most 0.10. Once a
case met these two criteria, four-parameter logistic curves
were fit to the 7-point curve concentration data, with the
top fixed at the stimulated MFI fluorescence (ensuring all
curves for the same donor had the same top parameter).
Once fitted, the IC50 from a curve was accepted if the fol-
lowing conditions were met: (i1) the R2 of the fitted curve
was above 0.65, (i2) the standard error (SE) of the
log(IC50) corresponded to a fold change smaller than 8,
(i3) the SE of the slope parameter was smaller than 8, and
(i4) the difference in the MFI signal between the highest
and lowest compound concentrations was larger than
both half the distance between the fitted top and bottom
parameters for that donor, compound curve, and the stim-
ulated and unstimulated MFI signals for that case. If more
than 25% of the curves for a compound were removed,
the entire case was removed from further analysis.
Estimation and comparison of mean IC50 values
Statistical analysis and comparison of IC50 values were
conducted by fitting statistical mixed effect models to
the log(IC50), including a random effect for donor and
fixed effects for compound for each stimulation, cell
type, and pSTAT combination. In cases where data were
collected in multiple batches, a batch-fixed effect was
added to the model to account for any systematic differ-
ences between batches. Reported IC50 values corre-
sponded to the least squares means of the compound
effects from the model. Reported p values were adjusted
for multiplicity by using a Bonferroni correction within
each stimulant and pSTAT combination.
Pharmacokinetic profiles
The PK profiles of baricitinib were estimated from a
two-compartment model with zero-order absorption
that was developed using data from patients with RA
from phase 2 and phase 3 clinical trials with once daily
(QD) 2- or 4-mg doses [11]. The PK profiles of upadaci-
tinib were obtained from published data using RA scaled
healthy volunteer profiles in a dose-proportional manner
for QD 15- or 30-mg doses [12, 13]. The PK profiles of
tofacitinib were estimated from a one-compartment
model with zero-order absorption using data from pa-
tients with RA from phase 3 clinical trials with twice
daily 5- or 10-mg doses [14].
Estimation and comparison of time above IC50 and daily
percent inhibition
The individual 4PL CRCs were combined with population
PK curves to calculate time above IC50 and average daily
percent inhibition. Protein binding effects were accounted
for by replacing the in vitro IC50 with an adjusted IC50
value computed by dividing the IC50 value for each donor
by the proportion of compound unbound (baricitinib 50%,
upadacitinib 54%, and tofacitinib 60%). The time above
IC50 was defined as the time the (linearly interpolated) PK
concentration was above the adjusted IC50. Protein-bound
adjusted CRCs were constructed by replacing the in vitro
IC50 value with the adjusted value. The average daily per-
cent inhibition for a subject was obtained by entering the
steady-state PK concentrations into the adjusted CRCs,
computing the area under this curve, and dividing it by 24
h. Using the individual donor values for time above IC50
and average daily percent inhibition, the same mixed model
used to fit the log(IC50) values was used to estimate and
compare mean times above IC50 and percent inhibitions.
No transformations were undertaken to keep the estimates
within the 0–24-h range (for time above IC50) and 0–100%
(for average daily inhibition). The values were truncated in
a few cases where the estimates fell outside the range.
Results
IC50 values for JAKis in cytokine-stimulated human PBMC
preparations
We first determined the specificity and potency of
different JAKis in inhibiting cytokine-induced
pSTATs in human peripheral blood mononuclear
cells (PBMCs). Following cytokine stimulation, quan-
tification of the inhibition of pSTATs elucidated that
IC50 values for any given JAKi were similar across
cell types and were dose-dependent. However, differ-
ences in IC50 values were observed between the
JAKis assessed. For the JAK1/3-dependent cytokines
IL-2, IL-4, IL-15, and IL-21, IC50 values were lowest
(most potent) for upadacitinib and tofacitinib and
highest (least potent) for baricitinib (Table 1 and
Additional file 1: Table S1).
Signal inhibition was assessed in monocytes for the
JAK2/2-dependent cytokines IL-3 and GM-CSF and the
JAK2/TYK2-dependent cytokine G-CSF (Table 1). IC50
values for IL-3, GM-CSF, and G-CSF signal inhibition
indicated highest potency for upadacitinib and bariciti-
nib and reduced potency for tofacitinib (Table 1). A
similar pattern was observed for IL-3 signal inhibition in
B cells (Additional file 1: Table S1).
IC50 values for IL-6 (JAK1/2) signaling in CD4+ T cells
and monocytes, and for IL-10- (JAK1/TYK2) stimulated
T cells and NK cells, were similar for baricitinib, upada-
citinib, and tofacitinib (Table 1 and Additional file 1:
Table S1). IC50 values for pSTAT3 inhibition in IL-10-
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stimulated monocytes indicated greatest potency for
upadacitinib and tofacitinib and reduced potency for
baricitinib (Table 1). IC50 values for pSTAT1 inhibition
in IFN-γ- (JAK1/2) stimulated monocytes indicated
highest potency for baricitinib and upadacitinib and re-
duced potency for tofacitinib (Table 1). IC50 values for
pSTAT1 inhibition in IFN-γ-stimulated B cells were
similar for baricitinib, upadacitinib, and tofacitinib (Add-
itional file 1: Table S1). Across cell types that had a re-
sponse, IC50 values for IFN-α- (JAK1/TYK2) induced
pSTAT1, 3, and 5 indicated the highest potency for upa-
dacitinib and baricitinib and lower potency for tofaciti-
nib (Table 1 and Additional file 1: Table S1).
Time above IC50
The potential clinical relevance of the foregoing was next
evaluated by examining the likely cell subset-specific inhib-
ition pattern in patients over a 24-h period, according to
the reported exposure levels (plasma concentrations during
the daily dosing cycle) for each agent. This analysis captures
“time-adjusted” inhibitory activity in terms of immune
modulatory function and could differ significantly among
agents with distinct PK properties. The number of hours
per day JAKi concentrations were above IC50 values for
each cytokine/pSTAT combination was determined using
calculated IC50 values and exposure data from JAKi-treated
subjects. For the JAK1/3-dependent cytokines IL-2, IL-4,
IL-15, and IL-21, tofacitinib spent the most time per day
above IC50 for the pSTAT induced by each cytokine across
cell types tested; time above IC50 was generally sequentially
less for upadacitinib and baricitinib (Table 2 and Add-
itional file 1: Tables S2–S4, and Fig. 1a). To illustrate this
pattern in NK cells, for IL-15/pSTAT5, time above IC50
was 17 and 23 h for tofacitinib 5- and 10-mg doses, 3.4 and
8.1 h for upadacitinib 15- and 30-mg doses, and 0 and 1 h
for baricitinib 2- and 4-mg doses, respectively. A similar re-
lationship was observed for IL-21/pSTAT3 (Table 2 and
Additional file 1: Tables S2–S4, and Fig. 1a).
For IL-3 and GM-CSF (JAK2/2), time above IC50 for
pSTAT5 inhibition in monocytes was generally highest
for upadacitinib and lower for baricitinib and tofacitinib
(Table 2 and Additional file 1: Table S3, and Fig. 1b, c).
To illustrate this pattern, for GM-CSF/pSTAT5 in
monocytes, time above IC50 was 12.6 and 18.1 h for upa-
dacitinib 15- and 30-mg doses, 2.5 and 9.2 h for bariciti-
nib 2- and 4-mg doses, and 2.2 and 9.0 h for tofacitinib
5- and 10-mg doses, respectively (Table 2 and
Additional file 1: Table S3, and Fig. 1c). For G-CSF
(JAK2/TYK2) in monocytes, time spent above IC50 for
pSTAT3 inhibition was most for tofacitinib and
Table 1 IC50 values in CD4+ T cells, NK cells, and monocytes
Stimulation/pSTAT CD4+ T cells NK cells Monocytes
Bari (nM) Upa (nM) Tofa (nM) Bari (nM) Upa (nM) Tofa (nM) Bari (nM) Upa (nM) Tofa (nM)
JAK1/3-dependent cytokines
IL-2/pSTAT5 29 10** 11*** 44 27* 15*** NS
IL-4/pSTAT6 48 18*** 18*** 22 8* 8*** 45 22** 35*
IL-15/pSTAT5 40 17*** 15*** 67 40* 22*** NS
IL-21/pSTAT3 64 20*** 22*** 62 24** 21*** 85 34 37
JAK2/2- or JAK2/TYK2-dependent cytokines
IL-3/pSTAT5 NS NS 26 12* 102***
G-CSF/pSTAT3 NS NS 65 84 97**
GM-CSF/pSTAT5 NS NS 30 13*** 97***
JAK1/JAK2/TYK2-dependent cytokines
IL-6/pSTAT3 61 58 56 NS 48 43 40
IL-10/pSTAT3 68 87 55 87 124 74 142 80*** 104*
IFN-γ/pSTAT1 NS NS 38 30 46***
IFN-α/pSTAT1 64 40 132*** 76 69 121*** 97 44** 163***
IFN-α/pSTAT3 27 17 51*** NS 14 6* 23***
IFN-α/pSTAT5 23 14 36** NS 13 5** 22***
Reported IC50 values are least squares estimates of mixed models as described in the “Statistical analysis” section. For G-CSF, IFN-γ, IL-2, IL-4, IL-6, IL-10, IL-15, and
IL-21, reported IC50 values are based on two batches of data amounting to 12 donors for baricitinib and 6 donors for upadacitinib and tofacitinib; for GM-CSF, IFN-
α, and IL-3, reported IC50 values are based on three batches of data amounting to 10 donors for baricitinib, 6 donors for upadacitinib, and 4 donors for tofacitinib.
The primary pSTAT observed for each stimulus is reported in the table. Protein binding was not accounted for in the IC50 calculations
*p < 0.01, **p < 0.001, ***p < 0.0001 compared to baricitinib
Bari baricitinib, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte-macrophage colony-stimulating factor, IC50 half maximum inhibitory
concentration, IFN interferon, IL interleukin, JAK Janus kinase, NK natural killer, NS no stimulation, pSTAT phosphorylated signal transducer and activator of
transcription, Tofa tofacitinib, TYK tyrosine kinase, Upa upadacitinib
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upadacitinib and least for baricitinib (Table 2 and
Additional file 1: Table S3).
For IL-6-induced CD4+ T cells and monocytes, time
above IC50 for pSTAT3 inhibition was generally high-
est for tofacitinib, decreased for upadacitinib, and least
for baricitinib (Table 2 and Additional file 1: Table S3,
and Fig. 1d). To illustrate this pattern, for IL-6/
pSTAT3 in CD4+ T cells, time above IC50 was 7.3 and
14.8 h for tofacitinib 5- and 10-mg doses, 0.6 and 5.5 h
for upadacitinib 15- and 30-mg doses, and 0 and 1.9 h
for baricitinib 2- and 4-mg doses, respectively (Table 2
and Additional file 1: Table S3, and Fig. 1d). This pat-
tern was also generally observed for JAKis in IFN-γ-
induced cell types (Table 2 and Additional file 1: Ta-
bles S2–S4, and Fig. 1e). For cell types stimulated by
IL-10, time above IC50 for pSTAT3 inhibition was gen-
erally highest for tofacitinib and least for upadacitinib
and baricitinib (Table 2 and Additional file 1: Tables
S2–S4). For cell types stimulated by IFN-α, time above
IC50 for pSTAT inhibition was generally the most for
upadacitinib and tofacitinib and the least for bariciti-
nib (Table 2 and Additional file 1: Table S2–S4).
Percent STAT inhibition
The JAK inhibitors were next compared by calculating the
percent inhibition of STAT phosphorylation over a 24-h
interval to determine the functional consequence of JAK
inhibition reflected by the magnitude and duration of in-
hibition of the phosphorylation of their most proximal
substrates. Concentration-response curves combined with
Table 2 Hours per day above IC50 in CD4+ T cells, NK cells, and monocytes: baricitinib 4 mg
Stimulation/pSTAT CD4+ T cells NK cells Monocytes
Bari
4 mg
Upa
15 mg
30mg
Tofa
5 mg
10mg
Bari
4 mg
Upa
15mg
30mg
Tofa
5 mg
10mg
Bari
4 mg
Upa
15 mg
30mg
Tofa
5 mg
10mg
JAK1/3-dependent cytokines
IL-2/pSTAT5 9 15.3*
20.6**
23.8***
24.2***
4.5 6.6
10.5**
21.4***
24.0***
NS
IL-4/pSTAT6 3.7 9.9
14.4**
19.6***
24.2***
12.6 17.5
22.3*
24.0***
24.0***
4.5 8.2
12.3**
12.3***
19.7***
IL-15/pSTAT5 5.5 10.4**
14.5***
21.2***
24.0***
1 3.4
8.1**
17.0***
23.0***
NS
IL-21/pSTAT3 0.7 9.0***
13.1***
17.0***
23.6***
1.2 7.7**
11.6***
17.5***
23.9***
0 4.4
8.6*
12.5*
18.9**
JAK2/2- or JAK2/TYK2-dependent cytokines
IL-3/pSTAT5 NS NS 10.1 13.0
18.3**
0.3***
8.1
G-CSF/pSTAT3 NS NS 1.4 0.1
3.2
2.3
8.5*
GM-CSF/pSTAT5 NS NS 9.2 12.6
18.1**
2.2***
9.0
JAK1/JAK2/TYK2-dependent cytokines
IL-6/pSTAT3 1.9 0.6
5.5
7.3*
14.8***
NS 3.6 3.1
7.6*
10.8*
18.2***
IL-10/pSTAT3 1.2 0
2.8
7.6*
15.1***
0.4 0
0.5
4.2*
11.8***
0 0.6
3.5
0.8
7.8***
IFN-γ/pSTAT1 NS NS 6 5.8
9.7*
9.4**
16.8***
IFN-α/pSTAT1 0.9 3.6
8.1**
0
5.2
0.2 0
4.8**
0.1
5.7***
0 2.9
7.5***
0
2.8***
IFN-α/pSTAT3 9.6 10.4
15.0
8.0
15.5***
NS 18.2 21.7
23.7
16.6
23.2*
IFN-α/pSTAT5 12 12.9
17.2
12.2
19.6***
NS 19.8 21.9
23.5
17.2*
23.9**
Reported hours per day above IC50 are least squares estimates of mixed models as described in the “Statistical analysis” section. Protein binding was accounted
for in the calculations. JAKis were administered once daily (baricitinib and upadacitinib) or twice daily (tofacitinib)
*p < 0.01, **p < 0.001, ***p < 0.0001 compared to baricitinib 4 mg
Bari baricitinib, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte-macrophage colony-stimulating factor, IC50 half maximum inhibitory
concentration, IFN interferon, IL interleukin, JAK Janus kinase, JAKi JAK inhibitor, NK natural killer, NS no stimulation, pSTAT phosphorylated signal transducer and
activator of transcription, Tofa tofacitinib, TYK tyrosine kinase, Upa upadacitinib
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exposure data for JAKi-treated subjects revealed cytokine-
dependent similarities and differences in the magnitude of
pSTAT inhibition (Table 3 and Additional file 1: Tables
S5–S7). Percent STAT inhibition for IL-2, IL-4, IL-15, and
IL-21 signaling (JAK1/3) was generally highest for tofaciti-
nib and upadacitinib and least for baricitinib (Table 3 and
Additional file 1: Tables S5–S7, and Fig. 1a). For example,
in NK cells, percent STAT inhibition for IL-15/pSTAT5
was 62% and 79% for tofacitinib 5- and 10-mg doses, 27%
and 39% for upadacitinib 15- and 30-mg doses, and 12%
and 24% for baricitinib 2- and 4-mg doses, respectively. A
similar relationship was observed for IL-21/pSTAT3
(Table 3 and Additional file 1: Table S6, and Fig. 1a).
Percent STAT inhibition for IL-3 and GM-CSF (JAK2/
2) in monocytes was generally highest for upadacitinib
and sequentially less so for baricitinib and tofacitinib
(Table 3 and Additional file 1: Table S6, and Fig. 1b, c).
Percent STAT inhibition for GM-CSF/pSTAT5 in
A B
C D
E
Fig. 1 JAKi exposure curves for select cytokines. The number of hours per day JAKi concentrations are above IC50 values is shown for IL-21/
pSTAT3 in NK cells (a), IL-3/pSTAT5 in monocytes (b), GM-CSF/pSTAT5 in monocytes (c), IL-6/pSTAT3 in CD4+ T cells (d), and IFN-γ/pSTAT1 in
monocytes (e). Panels a–e include the average daily percent STAT inhibition. Protein binding was accounted for in the calculation of hours per
day above IC50 and average daily percent STAT inhibition, and the IC50 values were corrected for the compound-bound proportion. *p < 0.01,
**p < 0.001, ***p < 0.0001 compared to baricitinib 2 mg; †p < 0.01, ††p < 0.001, †††p < 0.0001 compared to baricitinib 4 mg. Bari, baricitinib; BID,
twice daily; GM-CSF, granulocyte-macrophage colony-stimulating factor; h, hours; IC50, half maximum inhibitory concentration; IFN, interferon; IL,
interleukin; JAK, Janus kinase; JAKi, JAK inhibitor; NK, natural killer; pSTAT, phosphorylated STAT; QD, once daily; STAT, signal transducer and
activator of transcription; Tofa, tofacitinib; Upa, upadacitinib
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monocytes was 55% and 65% for upadacitinib 15- and
30-mg doses, 32% and 45% for baricitinib 2- and 4-mg
doses, and 23% and 37% for tofacitinib 5- and 10-mg
doses, respectively (Table 3 and Additional file 1: Table
S6, and Fig. 1c). A similar trend was observed for IL-3-
induced B cells. Percent STAT inhibition for G-CSF/
pSTAT3 (JAK2/TYK2) in monocytes was highest for
tofacitinib and less for upadacitinib and baricitinib
(Table 3 and Additional file 1: Table S6).
For cells stimulated by IL-6 (JAK1/2) and IL-10
(JAK1/TYK2), percent STAT inhibition was generally
highest for tofacitinib and less for upadacitinib and bar-
icitinib (Table 3 and Additional file 1: Table S5–S7, and
Fig. 1d). For IL-6/pSTAT3 in CD4+ T cells, percent
STAT inhibition was 39% and 54% for tofacitinib 5-
and 10-mg doses, 22% and 33% for upadacitinib 15-
and 30-mg doses, and 17% and 29% for baricitinib 2-
and 4-mg doses, respectively (Table 3 and Add-
itional file 1: Table S6, and Fig. 1d). A similar trend was
observed in IFN-γ- (JAK1/2) induced cell types (Table 3
and Additional file 1: Tables S5–S7, and Fig. 1e). The
percent STAT inhibition for IFN-α- (JAK1/TK2) in-
duced pSTAT1, 3, and 5 was generally highest for upa-
dacitinib and tofacitinib and less for baricitinib, across
cell types (Table 3 and Additional file 1: Table S5).
Discussion
The introduction of multiple JAKis into clinical practice,
each with distinct selectivity across the JAK family mem-
bers as determined by in vitro kinase assays, poses
Table 3 Average daily percent STAT inhibition in CD4+ T cells, NK cells, and monocytes: baricitinib 4 mg
Stimulation/pSTAT CD4+ T cells NK cells Monocytes
Bari
4 mg
Upa
15mg
30mg
Tofa
5 mg
10mg
Bari
4 mg
Upa
15 mg
30mg
Tofa
5 mg
10mg
Bari
4 mg
Upa
15mg
30mg
Tofa
5 mg
10mg
JAK1/3-dependent cytokines
IL-2/pSTAT5 44 60*
71***
78***
89***
34 36
48**
72***
85***
NS
IL-4/pSTAT6 30 45*
57***
69***
84***
52 61
71**
82***
91***
33 40
52**
51***
70***
IL-15/pSTAT5 36 47**
59***
72***
85***
24 27
39**
62***
79***
NS
IL-21/pSTAT3 27 44***
55***
61***
76***
27 40*
52***
61***
76***
22 34
45*
46*
63**
JAK2/2- or JAK2/TYK2-dependent cytokines
IL-3/pSTAT5 NS NS 47 52
61**
27***
42
G-CSF/pSTAT3 NS NS 25 17*
26
27
40**
GM-CSF/pSTAT5 NS NS 45 55
65**
23***
37***
JAK1/JAK2/TYK2-dependent cytokines
IL-6/pSTAT3 29 22
33
39*
54***
NS 32 27
39
46***
61***
IL-10/pSTAT3 27 21
29
39*
53***
23 14*
21
34**
48***
14 17
26*
25***
40***
IFN-γ/pSTAT1 NS NS 37 34
46*
43**
61***
IFN-α/pSTAT1 29 32
43*
24**
36**
25 21
31
23
37***
21 28
40***
21
32***
IFN-α/pSTAT3 45 48
61
40
55*
NS 62 72
81*
60
76*
IFN-α/pSTAT5 50 52
64
49
64**
NS 67 75
83*
62*
78**
Reported average daily percent STAT inhibition values are least squares estimates of mixed models as described in the “Statistical analysis” section. Protein
binding was accounted for in the calculations. JAKis were administered once daily (baricitinib and upadacitinib) or twice daily (tofacitinib)
*p < 0.01, **p < 0.001, ***p < 0.0001 compared to baricitinib 4 mg
Bari baricitinib, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte-macrophage colony-stimulating factor, IFN interferon, IL interleukin, JAK Janus
kinase, JAKi JAK inhibitor, NK natural killer, NS no stimulation, pSTAT phosphorylated STAT, STAT signal transducer and activator of transcription, Tofa tofacitinib,
TYK tyrosine kinase, Upa upadacitinib
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obvious questions as to the relative functional impact of
such differences. Herein, we characterized the in vitro
cellular pharmacology of baricitinib, upadacitinib, and
tofacitinib, coupled to their in vivo PK, to determine
their effects (at human oral doses that are approved or
included in late phase clinical studies) on distinct cyto-
kine pathways involved in the pathogenesis of RA.
Tofacitinib and upadacitinib, for example, were the most
potent inhibitors of the JAK1/3-dependent cytokines
tested. Moreover, lower IC50 values and increased time
above IC50 for tofacitinib and upadacitinib, compared for
example with baricitinib, translated to a greater overall in-
hibition of STAT signaling during the 24-h dosing interval
for JAK1/3-dependent cytokines. Inhibition of this par-
ticular pathway may have potential impact on lymphocyte
activation. Notably, IL-15 and IL-21 induce the matur-
ation and function of NK cells and this may be of rele-
vance to the changes in peripheral blood NK cell numbers
reported in JAKi trials in RA [9, 15–19]. Relationships be-
tween the durability of STAT inhibition by any given JAKi
and overall changes in lymphocyte subpopulations ob-
served in RA clinical trials with these molecules remains
to be determined.
Upadacitinib, baricitinib, and tofacitinib inhibited the
JAK2/2 or JAK2/TYK2 signaling cytokines IL-3, GM-
CSF, and G-CSF, albeit to varying degrees. Upadacitinib
proved the most potent inhibitor of IL-3 and GM-CSF
(JAK2/2), followed by baricitinib and tofacitinib, while
tofacitinib proved the most potent inhibitor of G-CSF
(JAK2/TYK2), followed by upadacitinib and baricitinib.
Both G-CSF and GM-CSF may contribute to RA patho-
genesis through the activation, differentiation, and sur-
vival of myeloid cells [20]. Indeed, blockade of GM-CSF
receptor with the humanized monoclonal antibody mav-
rilimumab was effective in a phase 2 clinical trial in RA
[21]. Baricitinib and other JAKis with activity against
JAK2 may attenuate RA pathogenesis in part through
inhibiting GM-CSF-mediated cellular responses.
With respect to JAK1/2-dependent cytokine signaling,
baricitinib, upadacitinib, and tofacitinib were all inhibitors
of IL-6 and IFN-γ (JAK1/2), and IL-10 and IFN-α (JAK1/
TYK2) signaling, although differences in potency emerged.
Tofacitinib proved the most potent inhibitor of IL-6, IFN-γ,
and IL-10 signaling, followed by upadacitinib and bariciti-
nib, while upadacitinib and tofacitinib were the most potent
inhibitors of IFN-α signaling. Interleukin-6 is a pleiotropic
pro-inflammatory cytokine that contributes to synovial in-
flammation, articular joint destruction, and some of the sys-
temic features observed in RA [22]. Baricitinib and other
JAKis may be effective in the treatment of RA in part by
IL-6 inhibition, which has been validated as a therapeutic
target in RA patients by the monoclonal antibody toci-
lizumab [23]. Interleukin-10, IFN-α, and IFN-γ are also
likely contributors to RA pathogenesis, and inhibition of
these responses may contribute to the mechanism of JAKis
in RA treatment; lesser inhibition of IL-10 may be desirable
as the net effects of this cytokine have been described as
anti-inflammatory in RA [4, 24].
Upadacitinib has been reported to be a selective JAK1
inhibitor [8, 9]. Data in this study, however, showed that
at clinically relevant doses, upadacitinib was the most
potent inhibitor among the drugs tested of the JAK2-
dependent cytokines IL-3 and GM-CSF. These findings
indicate that upadacitinib would also inhibit cytokines
other than those primarily dependent upon JAK1 at clin-
ically effective concentrations. Data in this study also
demonstrate that tofacitinib has moderate activity
against JAK2 and TYK2, in addition to activity against
JAK1 and JAK3. Together, these findings suggest that
conclusions about potency and selectivity drawn from
refined in vitro kinase assays may differ when consider-
ing the more biologically relevant concept of signal
blockade at the cellular level in the context of circulating
drug concentrations at doses used in humans.
There are limitations to the conclusions that can be
drawn from this analysis. One potential limitation with
this study is that high concentrations of cytokine can
right shift the IC50 values if the STAT substrate is
limiting. This could potentially be limiting our inter-
pretation of the data for upadacitinib. However, we
investigated this phenomenon and adjusted the cyto-
kine concentrations where necessary, but some cyto-
kines were either insensitive to concentration or could
not be lowered without compromising the data in an al-
ternate cell type or STAT readout. It would have been
valuable to assess the ability of each JAKi to impair the
half maximal response concentration (EC50) of these
cytokines, but would require extensive tuning of each
cytokine in each cell type, which is well beyond the
scope of this initial report. Another limitation was that
the statistical analysis of this study used a single, aver-
age PK profile and did not reflect inter-subject variabil-
ity. Furthermore, all IC50 values were calculated from
PBMCs derived from healthy volunteers and extrapo-
lated where available to RA patient exposure curves. Fi-
nally, while this study describes a reproducible cellular
test system in which to test the molecules, the drugs
were introduced to unstimulated healthy volunteer
cells, which were then stimulated. Looking at how such
molecules perform in previously activated cells may be
more relevant to in vivo inflammatory disease condi-
tions. This may warrant future study, for instance using
samples from patients with active inflammatory disease.
Conclusions
These data demonstrate that JAKis display different in
vitro pharmacologic profiles which, when coupled with
their in vivo PK profiles, suggest that they may work via
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modulating differing cytokine pathways to varying de-
grees and durations over a 24-h dosing interval. None of
the JAKis studied completely or continuously inhibited
an individual cytokine signaling pathway over the dosing
interval when assessed by STAT inhibition or time over
IC50, respectively. These observations may have implica-
tions for the efficacy and safety profiles observed with
different JAKis across different disease states. This in
turn may inform JAKi development tailored to capitalize
on the most clinically beneficial pharmacological fea-
tures that will emerge as several agents are established
in clinical practice.
Additional file
Additional file 1: Table S1. IC50 values in B cells and CD8+ T cells. Table
S2. Hours per day above IC50 in B cells and CD8+ T cells: baricitinib 4-mg.
Table S3. Hours per day above IC50 in CD4+ T cells, NK cells, and
monocytes: baricitinib 2-mg. Table S4. Hours per day above IC50 in B cells
and CD8+ T cells: baricitinib 2-mg. Table S5. Average daily percent STAT
inhibition in B cells and CD8+ T cells: baricitinib 4-mg. Table S6. Average
daily percent STAT inhibition in CD4+ T cells, NK cells, and monocytes:
baricitinib 2-mg. Table S7. Average daily percent STAT inhibition in B cells
and CD8+ T cells: baricitinib 2-mg. Figure S1. Select representative
histogram plots for cytokine-induced STAT phosphorylation (DOCX 278 kb)
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